A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

Also called NCT03560271

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 256 participants (enrolled count) (from the registry)
Sponsor
NovMetaPharma Co., Ltd. (from the registry)
Registry
  • NCT NCT03560271
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03560271. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-18 (actual); primary completion 2019-06-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Study of Cyclo-Z in Subjects With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Cyclo-Z
Intervention (Other)
Placebo
Lead sponsor
NovMetaPharma Co., Ltd. (class: industry)
Collaborator
InClin, Inc. (class: industry)
Collaborator
FGK Clinical Research GmbH (class: industry)

Record details

Record id
cardio:ct-nct03560271
Content hash
16693852b552e7425c916d0a73bad0f844c481e632e83f679ac65ce5684575f7